Enterprise Value
1.735B
Cash
731.4M
Avg Qtr Burn
-26.13M
Short % of Float
8.00%
Insider Ownership
16.64%
Institutional Own.
73.03%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
MORF-057 (α4β7 integrin) Details Colorectal cancer , Cancer, Ulcerative colitis, Crohns disease | Phase 2a Data readout |